• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by PAVmed Inc.

    7/28/25 4:09:40 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on July 28, 2025

     

    Registration No. 333-               

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    PAVMED INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   47-1214177
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    360 Madison Avenue, 25th Floor

    New York, NY 10017

    (Address of Principal Executive Offices) (Zip Code)

     

    PAVMED INC. SIXTH AMENDED AND RESTATED 2014 LONG-TERM INCENTIVE EQUITY PLAN

    (Full title of the plan)

     

    Dr. Lishan Aklog, Chairman and Chief Executive Officer

    PAVmed Inc.

    360 Madison Avenue, 25th Floor

    New York, NY 10017

    (Name and address of agent for service)

     

    (917) 813-1828

    (Telephone number, including area code, of agent for service)

     

    with a copy to:

     

    David Alan Miller, Esq.

    Eric T. Schwartz, Esq.

    Graubard Miller

    The Chrysler Building

    405 Lexington Avenue, 44th floor

    New York, NY 10174

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐   Accelerated filer ☐
      Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    In accordance with the provisions of Rule 462 promulgated under the Securities Act of 1933, as amended, the Registration Statement will become effective upon filing with the Securities and Exchange Commission.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement is filed by PAVmed Inc. (the “Company”) to register an additional 2,500,000 shares of the Company’s common stock issuable pursuant to the Company’s Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan (the “Plan”), which are newly reserved for issuance under the Plan as a result of an amendment to the Plan approved by the Company’s board of directors and stockholders, and consists of only those items required by General Instruction E to Form S-8. The Company hereby incorporates by reference into this registration statement the contents of the prior registration statements on Form S-8 relating to the Plan, filed with the Securities and Exchange Commission (the “SEC”) on May 20, 2021 (File No. 333-256343), August 4, 2021 (File No. 333-258459), and April 13, 2022 (File No. 333-264271), February 10, 2023 (File No. 333-269700), February 6, 2024 (File No. 333-276904) and January 31, 2025 (File No. 333-284637).

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.*

     

    Item 2. Registrant Information and Employee Plan Annual Information.*

     

    * The information required by this Part I is omitted from this Registration Statement in accordance with rules and regulations under the Securities Act of 1933, as amended (“Securities Act”), and the Note to Part I of Form S-8. The documents containing the information specified in this Part I will be sent or given to employees, officers, directors or others as specified by Rule 428(b)(1) under the Securities Act. Such documents and the documents incorporated by reference herein pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents that we have previously filed with the SEC are incorporated by reference in this registration statement (excluding any reports or portions thereof that are furnished under Item 2.02 or Item 7.01 and any exhibits included with such items):

     

      ● The annual report on Form 10-K for the fiscal year ended December 31, 2024 (filed on March 24, 2025).
         
      ● The quarterly report on Form 10-Q for the period ended March 31, 2025 (filed on May 15, 2025).
         
      ● The current reports on Form 8-K dated January 15, 2025 (filed on January 15, 2025), January 17, 2025 (filed on January 21, 2025), January 23, 2025 (filed on January 24, 2025), February 14, 2025 (filed on February 18, 2025), February 18, 2025 (filed on February 21, 2025), March 5, 2025 (filed on March 10, 2025), April 11, 2025 (filed on April 11, 2025), April 17, 2025 (filed on April 17, 2025), April 23, 2025 (filed on April 25, 2025), June 18, 2025 (filed on June 18, 2025) and June 23, 2025 (filed on June 24, 2025).
         
      ● The description of our common stock in the Form 8-A filed on January 29, 2016, together with any amendment or report filed under the Exchange Act for the purpose of updating such description, including Exhibit 4.1 to our annual report on Form 10-K for the fiscal year ended December 31, 2024.

     

    All documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), prior to the filing of a post-effective amendment which indicates that all the securities offered have been sold or which deregisters all securities then remaining unsold (excluding any reports or portions thereof that are furnished under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items) will be deemed to be incorporated by reference in this registration statement and to be a part of this registration statement from the respective date of filing.

     

    Any statement contained herein or in a document incorporated by reference herein will be modified or superseded for all purposes to the extent that a statement contained herein or in any other subsequently filed document which is incorporated by reference herein modifies or replaces the statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

     

    Notwithstanding the foregoing, we are not incorporating any document or portion thereof or information deemed to have been furnished and not filed in accordance with SEC rule.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Graubard Miller issued the opinion as to the legality of the shares of our common stock being registered pursuant to this registration statement.

     

    Item 8. Exhibits.

     

    See the Exhibit Index, which is incorporated herein by reference.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

      (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.

     

      (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing procedures, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on this 28th day of July, 2025.

     

      PAVMED INC.
         
      By: /s/ Lishan Aklog, M.D.
        Lishan Aklog, M.D.
        Chairman and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lishan Aklog, M.D. and Dennis M. McGrath, and each of them, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement, any and all amendments thereto (including post-effective amendments), and any amendments thereto and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures   Title   Date
               
    By: /s/ Lishan Aklog, M.D.   Chairman and Chief Executive Officer   July 28, 2025
      Lishan Aklog, M.D.   (Principal Executive Officer)    
               
    By: /s/ Dennis M. McGrath   President and Chief Financial Officer   July 28, 2025
      Dennis M. McGrath   (Principal Financial and Accounting Officer)    
               
    By: /s/ Michael J. Glennon   Vice Chairman and Director   July 28, 2025
      Michael J. Glennon        
               
    By: /s/ Sundeep Agrawal, M.D.   Director   July 28, 2025
      Sundeep Agrawal, M.D.        
               
    By: /s/ Tim Baxter   Director   July 28, 2025
      Tim Baxter        
               
    By: /s/ Ronald M. Sparks   Director   July 28, 2025
      Ronald M. Sparks        
               
    By: /s/ Debra J. White   Director   July 28, 2025
      Debra J. White        

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    3.1   Certificate of Incorporation (incorporated by reference to the Registrant’s Registration Statement on Form S-1, File No. 333-203569)
         
    3.2   Certificate of Amendment to Certificate of Incorporation, dated April 19, 2015 (incorporated by reference to the Registrant’s Registration Statement on Form S-1, File No. 333-203569)
         
    3.3   Certificate of Amendment to Certificate of Incorporation, dated October 1, 2018 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on October 2, 2018)
         
    3.4   Certificate of Amendment to Certificate of Incorporation, dated June 26, 2019 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on June 27, 2019)
         
    3.5   Certificate of Amendment to Certificate of Incorporation, dated July 24, 2020 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on July 27, 2020)
         
    3.6   Certificate of Amendment to Certificate of Incorporation, dated June 21, 2022 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on June 22, 2022)
         
    3.7   Certificate of Amendment to Certificate of Incorporation, dated December 5, 2023 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on December 5, 2023)
         
    3.8   Certificate of Amendment to Certificate of Incorporation, dated January 15, 2025 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on January 15, 2025)
         
    3.9   Certificate of Elimination of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K/A filed on April 20, 2018)
         
    3.10   Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K/A filed on April 20, 2018)
         
    3.11   Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on January 21, 2025)
         
    3.12   Amended and Restated Bylaws (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on January 15, 2021)
         
    4.1   Specimen PAVmed Inc. Common Stock Certificate (incorporated by reference to the Registrant’s Registration Statement on Form S-1, File No. 333-203569)
         
    5.1   Opinion of Graubard Miller (filed herewith)
         
    10.1   PAVmed Inc. Sixth Amended and Restated Long-Term Incentive Equity Plan (incorporated by reference to Annex A of the Supplement to Proxy Statement filed on Schedule 14A filed on May 9, 2025)
         
    23.1   Consent of Marcum LLP (filed herewith)
         
    23.3   Consent of Graubard Miller (included in Exhibit 5.1)
         
    24.1   Power of Attorney (included on the signature page hereto)
         
    107   Calculation of Filing Fee Table (filed herewith)

     

     

     

    Get the next $PAVM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    SEC Filings

    See more
    • SEC Form S-8 filed by PAVmed Inc.

      S-8 - PAVmed Inc. (0001624326) (Filer)

      7/28/25 4:09:40 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/24/25 8:15:29 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/18/25 5:00:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

      Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that  on Thursday, September 4, 2025, from 2:00 to 4:00 p.m. ET, MolDX-participating Medicare Administrative Contractors (MACs)—Palmetto GBA, CGS Administrators, Noridian Healthcare Solutions, and WPS Government Health Administrators—will convene a MolDX Contractor Advisory Committee (CAC) Meeting of medical experts as a critical step in the reconsideration of Local Coverage Determination (LC

      7/16/25 7:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

      Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK, June 24, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ("Veris"), today announced the completion of a private placement equity financing directly into Veris, yielding $2.5 million in proceeds (gross and net). This supplements a prior $2.4 million financing completed earlier this year.

      6/24/25 8:01:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

      Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, prim

      6/18/25 12:02:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

      3 - PAVmed Inc. (0001624326) (Issuer)

      3/14/25 7:53:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      10/23/24 4:36:47 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      9/20/24 4:13:39 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on PAVmed with a new price target

      Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

      3/30/21 6:22:24 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lake Street Capital reiterated coverage on PAVmed with a new price target

      Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

      2/22/21 4:33:18 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

      NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

      5/27/25 7:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Financials

    Live finance-specific insights

    See more
    • PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

      Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

      5/15/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      9/23/24 8:46:15 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      2/14/24 3:38:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care